SCHEMBL6731998

SCHEMBL6731998

CCS(=O)(=O)N(Cc1ccc(C)nc1)c1ccc(Oc2ccccc2OC)cc1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 10/20 0.61
HIF1A Q16665 1/20 0.42
EPAS1 Q99814 1/20 0.42
LPAR1 Q92633 4/20 0.42
LPAR5 Q9H1C0 4/20 0.42
NR3C1 P04150 1/20 0.42
PGR P06401 1/20 0.42
SLC6A2 P23975 1/20 0.41
SLC6A4 P31645 1/20 0.41
SLC6A3 Q01959 1/20 0.41
ALDH1A1 P00352 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
LMNA P02545 1/20 0.40
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6739545 0.89 GRM2 (0.58) GRM2HIF1AEPAS1LPAR1LPAR5
SCHEMBL6736188 0.89 GRM2 (0.78) GRM2LPAR1LPAR5
SCHEMBL6732057 0.88 GRM2 (0.57) GRM2HIF1AEPAS1LPAR1LPAR5
SCHEMBL6732751 0.88 GRM2 (0.73) GRM2NR3C1PGR
SCHEMBL6735080 0.86 GRM2 (0.80) GRM2ALDH1A1HTTLMNA
SCHEMBL6728034 0.85 GRM2 (0.54) GRM2HIF1AEPAS1LPAR1LPAR5
SCHEMBL6767846 0.82 BRD4 (0.50) GRM2
SCHEMBL6727498 0.82 GRM2 (0.62) GRM2LPAR1LPAR5NR3C1PGR
SCHEMBL6739595 0.81 GRM2 (0.75) GRM2ALDH1A1HTTLMNA
SCHEMBL6727725 0.79 GRM2 (0.47) GRM2LPAR1LPAR5NR3C1PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6800651-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY 2004-10-05 US claimed
US-20040006114-A1 Potentiators of glutamate receptors ELI LILLY AND COMPANY 2004-01-08 US claimed
EP-1255735-A2 PYRIDINE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2002-11-13 EP claimed
WO-2001056990-A2 PYRIDINE DERIVATES AS POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2001-08-09 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006114-A1 Potentiators of glutamate receptors GRM1, GRIN1, GRM2 GRM2 3/4885HIF1A 1147/4885EPAS1 2468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.